🇺🇸 FDA
Pipeline program

CB-012

CB12A

Phase 1 small_molecule terminated

Quick answer

CB-012 for Acute Myeloid Leukemia, in Relapse is a Phase 1 program (small_molecule) at Caribou Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Caribou Biosciences
Indication
Acute Myeloid Leukemia, in Relapse
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials